DRUG USE INDICATORS IN PATIENTS WITH TYPE 2 DIABETES IN A TERIARY HEALTHCARE FACILITY IN NIGERIA
Keywords:
Drug utilization, Type 2 diabetes, Antidiabetics, Treatment guideline, Rational drug useAbstract
Objective: The study analyzed the utilization pattern of antidiabetic drugs at the outpatient clinic of a teaching hospital in Nigeria to document information for enhancing the rational use of drugs in type 2 diabetes.
Methods: A retrospective analysis of prescription records of patients with type2 diabetes, seen between the months of May and October, 2013 was carried out; adapting the World Health Organization's (WHO) recommended drug use indicators. Data was analyzed for drug use indicators, concurrent illnesses and co-prescribed medications.
Results: A total of 286 prescriptions of T2DM were collected and analyzed. Mean age of patients was 61(±11.8) years. The number of drugs per prescription averaged 4(±1.6), with majority of prescriptions, 70% containing between 3 and 5 drugs each. Metformin (55.8%) was the most commonly prescribed antidiabetic drug followed by glibenclamide (35.1%). Antibiotics were prescribed in 11% of encounters. The percentage of drugs prescribed by generic name was 58%. Hypertension was identified in 42.2% of the diabetic patients as the most co-existing condition.
Conclusion: The study suggests a significant compliance to T2DM treatment guidelines but with scope for improved rational use of drug to reduce the risk of drug therapy problems and enhance patients' quality of life. It provides a baseline data for further studies on institutional drug use in diabetes.
Downloads
References
International Diabetes Federation. Diabetes Atlas. Fifth Edition; 2011.
World Health Organization (WHO) Fact sheet to the ministerial Technical committee working group (TWG) on the UN High level meeting on non-communicable diseases (NCDs) WHO report for Nigeria. Abuja July; 2011.
Akingbe OO. Non-communicable diseases in Nigeria: National Survey on hypertension, coronary heart diseases, diabetes mellitus, haemoglobinopathy, G6PD Deficiency and Anemia –National Expert Committee on Non-Communicable diseases. Federal Ministry of Health and Social Services. Lagos; 1997.
Ogbonna BO, Ezenduka CC, Opara CA, Aghara LG. Drug therapy problems in type 2 diabetes in a tertiary hospital in Nigeria. Int J Innovative Res Development 2014;3(1):494-502.
Israili ZH. Advances in the treatment of type 2 diabetes mellitus [published online ahead of print October 14] Am J Ther; 2009.
Edelman SV, Henry RR. Diagnosis and Management of type 2 Diabetes. West Islip, NY: Professional Communications, Inc; 2007.
WHO; Introduction to Drug Utilization Research/WHO International Working Group for Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services; 2003.
Nyenwe EA, Odia OJ, Ihekweaba AE, Ojule A, Babtunde S. Type 2 diabetes in adult Nigerians: a study of its prevalence and risk factors in port harcourt Nigeria. Diabetes Res Clin Prac 2003;62:177-85.
Jimoh AO, Sabir AA, Chika A, Sani Z. Pattern of anti-diabetic drugs use in a diabetic outpatient clinic of a tertiary health institution in Sokoto, north-western Nigeria. J Med Sci 2011;11:241-5.
Zinmet P. Type 2 (non-insulin dependent) diabetes: an epidemiological overview. Diabetol 1982;22:399-411.
Johnson TO. Comparative study of screening methods for diabetes mellitus in the elderly Nigerian subjects. West Afr Med J Niger Pract 1971;20:243-6.
Enwere OO, Falade GO, Slako BL. Prescribing pattern at the medical outpatient clinic of a tertiary hospital in southwestern Nigeria. Pharm Drug Saf 2007;16:1244-9.
Adams OP, Carter AO. Are primary care practitioners in barbados following diabetic guidelines? A chart audit with comparison between public and private care sectors. Boil Med Chem Res Notes 2011;4:101186/1756-0500-4-199.
Adibe MO, Aguwa CN, Ukwe CV, Okonta JM, Udeogoranya PO. Outpatient utilization of anti-diabetic drugs in the south-eastern Nigeria. Int J Drug Dev Res 2009;1:27-36.
Bnouham M, Ziyyat A, Mekhfi H, Tahri A, Legssyer A. Medicinal plants with potential anti-diabetic activity. A review of ten years of herbal medicine research. Int J Diab Met 2006;14:1-25.
Ezenduka CC, Ubochi VN, Ogbonna BO. The utilization pattern and cost analysis of psychotropic drugs at a neuropsychiatry hospital in Nigeria. 2014;4(3):325-37.
Ontarget Investigators, Yusuf S, Teo KK, Pogue J, Dyal L. Temisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
IDF. Clinical guidelines task force. Global guidelines for type 2 diabetes: International Diabetes Federation, Brussels; 2005.
CDA. Clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Diabetes Association; 2008.
NIHCE. Type 2 diabetes: The management in primary and secondary cure (update). National Institute for Health and Clinical Excellence; 2010.
Nathan, DM, Buse JB, Davidson MB, Heine R J, Holman RR, Sherwin R, et al. management of hypoglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A conse sus statement from the American Diabetes Association and the European Association for the study of diabetes. Diabetol 2006;29:1963–72.